Protara Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on the stock and has a $23.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight Protara Therapeutics’ potential in the market. One of the primary reasons is the promising progress of TARA-002 in treating non-muscle invasive bladder cancer (NMIBC), which is seen as an underappreciated opportunity. The drug’s ease of use, safety, and competitive efficacy profile are expected to become more apparent as other programs show less impressive results. The upcoming release of interim data from the ADVANCED-2 trial and ongoing discussions with the FDA regarding BCG-naïve patients could further solidify TARA-002’s position in the NMIBC market.
Additionally, the company’s IV choline chloride program, which targets patients needing parenteral support, is backed by Orphan Drug and Fast Track designations, indicating its potential as a valuable therapy. The ongoing phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations also shows promising preliminary results. With a strong cash runway extending into mid-2027, Protara is well-positioned to deliver significant data across its diversified portfolio, reinforcing the Buy rating with a price target of $23.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, Candel Therapeutics, and ImmunityBio. According to TipRanks, Y. Maldonado has an average return of 17.5% and a 51.92% success rate on recommended stocks.